Skip to content
Triangle logo TriangleGet started
← Childhood Acute Myeloid Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Low-risk patients

Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Childhood AML / Postremission Therapy for AML / HSCT / Risk stratification for transplant

Patients receiving contemporary chemotherapy regimens have improved outcome if they have favorable prognostic features (low-risk cytogenetic or molecular variants). This finding and the lack of demonstrable superiority for HSCT in this patient population means that such patients typically receive matched-family donor (MFD) HSCT only after first relapse and the achievement of a second CR.[65,73-75]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice